



# DWARIKESH SUGAR INDUSTRIES LIMITED

Corp. off.; 511, Maker Chambers V, 221, Nariman Point, Mumbai – 400021. Tel.: 2283 2486, 2204 2945, Fax : 2204 7288  
E Mail : dsilbom@dwarikesh.com Website : www.dwarikesh.com, CIN : L15421UP1993PLC018642

REF: DSIL/2020-21/084

October 28, 2020

Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai - 400 001  
Fax: 22723 2082 /3132

National Stock Exchange of India Limited  
“Exchange Plaza”  
Bandra - Kurla Complex,  
Bandra [E], Mumbai - 400 051

**Scrip Code - 532610**

**Scrip Code - DWARKESH**

**Sub: Conference call with respect to financial results for quarter (Q2) and half year ended September 30, 2020 and Outlook**

Dear Sir,

Pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that a conference call on Tuesday, November 03, 2020 at 3.30 p.m. (IST) w.r.t. financial results for the quarter (Q2) and half year ended September 30, 2020 and outlook of the company is organized by **B & K SECURITIES (BATLIVALA & KARANI SECURITIES INDIA PRIVATE LIMITED)** as per details in the annexed invite (copy of invite is attached).

Kindly take the same on record.

Thanking you,

Yours faithfully,

**B. J. Maheshwari**  
**Managing Director & CS cum CCO**  
**(DIN 00002075)**

**Encl: as above**



**CONCALL INVITE**

**B&K Securities shall hold  
a Conference Call of  
Dwarikesh Sugar  
Industries Ltd.**

**CIN: L15421UP1993PLC018642**

to discuss the Q2FY21 Financial performance  
on **Tuesday, 3rd November 2020 at 3:30 pm IST**

**The Management Team will be represented by:  
Mr. Vijay S. Banka – Managing Director**

**You are cordially invited to join the conference call**

**Dial-in Numbers (Access code-281324 and press # key)  
Universal Dial In: +91 22 6608 5555 / +91 22 4194 2222  
Toll free numbers: 1800 102 7129 / 1800 209 7129**

**International Dial-in Numbers (press \*0 when prompted for access code)**

Country	Local Access	Toll-Free Access
Australia	+61-731-230-085	1800-057-144
Canada	+1-347-338-2740	1-866-712-7129 1-844-574-1293
Hong Kong	+852-3018-6603	800-905-107
Singapore	+65-3157-5031	800-101-2406
UK	+44-20-3463-9329	0800-031-5725 0808-101-3882
USA	+1-347-338-2740	1-866-712-7129 1-844-574-1293

## [Express Join with No Wait Time](#)

**Note:**

- **The link will be activated 10 minutes before the conference start time.**
- **No pre-registration required**

For further information, please contact  
**Mr. Anupam Goswami / Mr. Ratish Nair**  
**Batlivala & Karani Securities India Pvt. Ltd.**

+91 90511 63951 / +91 98929 71418

[anupam.goswami@bksec.com](mailto:anupam.goswami@bksec.com) / [ratish.nair@bksec.com](mailto:ratish.nair@bksec.com)

Regards

B&K Research

[research.equities@bksec.com](mailto:research.equities@bksec.com)

+91-22-4031 7000

**Disclaimer**

This report was prepared, approved, published and distributed by Batlivala & Karani Securities India Private Limited ("B&K") located outside of the United States (a "non-US Group Company"), which accepts responsibility for its contents. It is distributed in the U.S. by Enclave Capital, a U.S. registered broker dealer, on behalf of B&K, only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act") pursuant to the exemption in Rule 15a-6. Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. Outside the United States, this report is distributed by B&K or an authorized affiliate of B&K.

The report has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. B&K has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, B&K accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. B&K provides the information for the purpose of the intended recipient's analysis and review and recipients are advised to verify the factual accuracy, assumptions, calculations and completeness of the information.

This report was produced by B&K solely for information purposes and for the use of the recipient. It is not to be reproduced, redistributed under any circumstances and is not to be copied or made available to any person other than the recipient. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability

to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions. This document does not constitute an offer of, or an invitation by or on behalf of B&K or its affiliates or any other company to any person, to buy or sell any security.

The views of any Analyst reflected in this report are given in compliance with the Research Analyst Regulations, 2014. All analysts covering the securities/ companies mentioned in this report have complied with the appropriate set of rules, regulations & procedures in their detailed coverage report(s) of the respective securities/companies. It is important to note that any dispute with respect to this Research Report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

#### **Analyst Certification**

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

1. B&K or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
2. B&K or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. B&K or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more person of B&K or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
5. B&K or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
6. As of the publication of this report, Enclave Capital does not make a market in the subject securities.

#### **Important US Regulatory Disclosures on Subject Companies**

Enclave Capital is the distributor of this document in the United States of America. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital (19 West 44th Street, suite 1700, New York, NY 10036). Tel No: (646) 454 8600).

[Unsubscribe from this distribution](#)